The prevalence of type 2 diabetes is a major global health challenge affecting 9% of the population. T2D is a condition associated with serious microvascular and macrovascular complications. Obesity, as the major risk factor for the occurrence of T2D, is also the main target of therapeutic options aiming to reach a state of disease remission. According to the ADA consensus from 2021., remission is a state in which T2D is no longer active and does not worsen, but there is a possibility of a recurrence of hyperglycemia. The criterion for the remission of T2D is the value of HbA1c < 6.5%, which is present for 3 or more months without the use of antihyperglycemic agents. Changing lifestyle habits related to diet and exercise significantly contributes to weight loss, and this is exactly what studies have shown to have a great impact on the return of euglycemia. The DiRECT clinical trial, designed to determine whether a structured, intensive weight management program delivered through the primary care system can be a viable treatment for achieving sustained normoglycemia, found that among subjects who lost > 15 kg, as many as 70% achieved T2D remission. In addition to lifestyle modification, significant weight loss can be achieved with the use of antiobesity drugs or bariatric surgery methods. The fact that remission of T2D is possible, especially if duration of diabetes is less than six years, should be actively promoted and communicated with patients. Being motivated to achieve remission by changing lifestyle habits and/or applying other methods of obesity treatment, may help permanently avoid the occurrence of diabetes complications that are known to shorten life expectancy, reduce the quality of life and put a significant financial burden on the healthcare system.